SciClone Pharma Gains China Rights for Two CV Drugs in $50 Million Deal

SciClone Pharma in-licensed China marketing rights to two cardiovascular drugs from The Medicines Company, a deal that includes up to $50.5 million in upfront and milestone payments. SciClone is based in California, though it focuses on the China market. Over the past two years, SciClone has been actively developing its cardiovascular portfolio: in 2013, the company acquired China rights for two other CV drugs, both of which await CFDA approval. More details.... Stock Symbols: (NSDQ: SCLN) (NSDQ: MDCO) Share this with colleagues: // //